Company news

bioAffinity Technologies, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume

November 5, 2025

bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases

October 28, 2025

bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025

October 20, 2025

bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer

October 16, 2025

bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements

October 15, 2025

bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

October 9, 2025

bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

October 8, 2025

bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025

October 7, 2025

bioAffinity Technologies Announces Closing of $4.8 Million Public Offering

September 30, 2025

bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering

September 29, 2025

bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung

September 26, 2025

bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025

September 17, 2025

Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules

September 9, 2025

U.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA

September 3, 2025

bioAffinity Technologies Appoints New Members to Board of Directors

August 18, 2025

bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

August 14, 2025

bioAffinity Technologies Reports Second Quarter 2025 Results

August 14, 2025

bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

August 13, 2025

bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales

August 13, 2025

Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results

July 29, 2025

Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools

July 23, 2025

Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company’s Noninvasive Lung Cancer Diagnostic

July 22, 2025

bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic

July 15, 2025

Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging

July 9, 2025

bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

June 26, 2025

bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy

June 24, 2025

bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas’ Leadership Board

June 11, 2025

bioAffinity Technologies Works With Cardinal Health™ OptiFreight® Logistics to Help Meet Demand for CyPath® Lung

June 3, 2025

bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics

May 28, 2025

bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

May 20, 2025

bioAffinity Technologies Reports First Quarter 2025 Results

May 15, 2025

Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer

May 8, 2025

bioAffinity Technologies Announces Closing of $3.25 Million Offering

May 7, 2025

bioAffinity Technologies Announces Pricing of $3.25 Million Offering

May 6, 2025

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

April 17, 2025

bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

March 31, 2025

Case Study: bioAffinity Technologies’ CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

March 26, 2025

Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

March 19, 2025

Physicians’ Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer

March 13, 2025

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

March 6, 2025

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

February 26, 2025

bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

February 25, 2025

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic

January 21, 2025

bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung

January 12, 2025

bioAffinity Technologies Set for Continued Expansion in 2025

December 11, 2024

bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

November 3, 2024

bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung

October 29, 2024

bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement

October 20, 2024

bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement

October 17, 2024

bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer

October 9, 2024

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 6 decks. Every deck is listed under its year.